|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 469.36 Million
|
|
Market Size (2030)
|
USD 627.03 Million
|
|
CAGR (2025-2030)
|
4.92%
|
|
Fastest Growing Segment
|
Genetic Engineering
|
|
Largest Market
|
Germany
|
Market Overview
The Europe Protein Sequencing Market was
valued at USD 469.36 Million in 2024 and is expected to reach USD 627.03
Million by 2030 with a CAGR of 4.92%. The Europe
Protein Sequencing Market is witnessing significant momentum driven by the
growing application of proteomics in pharmaceutical and biotechnology research.
As the demand for precision medicine continues to rise, protein sequencing is
becoming a cornerstone in understanding disease mechanisms at the molecular
level. Researchers are increasingly leveraging protein sequence analysis to identify
and validate biomarkers, leading to more targeted therapeutic development. The
rising incidence of chronic and complex diseases is pushing pharmaceutical
companies to adopt advanced sequencing techniques that enable efficient drug
discovery and development. The integration of protein sequencing into
personalized medicine workflows is also opening new avenues for diagnostics and
patient-specific treatment plans, further enhancing its relevance across
healthcare and life sciences.
A notable trend shaping the market is the growing
adoption of mass spectrometry-based platforms for high-throughput protein
analysis. Technological innovations in analytical tools and bioinformatics are
making sequencing faster, more accurate, and scalable. Automation of sample
preparation, improved software for protein structure prediction, and
cloud-based data analytics are streamlining workflows and expanding
accessibility across research facilities. Another key trend is the strategic
collaboration between academic institutions and industry players, aimed at
developing novel proteomic methods and accelerating translational research.
These partnerships are not only fostering innovation but also enabling rapid
commercialization of advanced sequencing tools.
Despite strong growth drivers, the market faces
several challenges. High capital investment required for setting up
sophisticated protein sequencing infrastructure remains a barrier for small and
mid-sized research organizations. Shortage of skilled professionals who can
operate and interpret complex sequencing data continues to limit widespread
adoption. Regulatory hurdles related to validation and approval of
sequencing-based diagnostics further slow down product launch cycles. Moreover,
the complexity of post-translational modifications and difficulty in sequencing
low-abundance proteins present technical limitations that researchers must
overcome. Addressing these challenges is essential for ensuring the sustainable
growth of the Europe Protein Sequencing Market in the years ahead.
Key Market Drivers
Surging
Demand for Precision Medicine and Biomarker Discovery
The surging demand for precision medicine and
biomarker discovery is a key driver for the Europe Protein Sequencing Market,
as healthcare increasingly shifts toward personalized treatment strategies.
Precision medicine aims to tailor medical treatments to individual patients
based on their genetic makeup, lifestyle, and environmental factors, making
protein sequencing an essential tool in identifying specific biomarkers
associated with diseases. By providing detailed insights into protein structure
and function, protein sequencing helps in pinpointing biomarkers that can be
used for early diagnosis, prognosis, and treatment monitoring, particularly in
complex diseases such as cancer, cardiovascular conditions, and neurological
disorders.
The identification and validation of biomarkers are
central to the development of targeted therapies, which are more effective and
have fewer side effects compared to traditional treatments. Protein sequencing
enables researchers and healthcare professionals to explore the functional
aspects of proteins, which are directly linked to disease mechanisms. This
growing focus on biomarker discovery has driven significant investment in
advanced sequencing technologies, which are capable of delivering high-resolution,
accurate, and reproducible results.
As the healthcare industry emphasizes more
personalized treatment regimens, the demand for robust, high-throughput
sequencing platforms continues to rise. Additionally, with advancements in
proteomics, pharmaceutical companies are increasingly adopting protein
sequencing technologies to accelerate drug discovery and to enhance the
development of targeted therapies. The trend toward precision medicine and
biomarker discovery is expected to remain a dominant force driving the growth
of the protein sequencing market in Europe, as both academic and clinical
research intensify their efforts to bring innovative solutions to the healthcare
sector.
Rising
Academic and Government Research Funding
The rising academic and government research funding
is a pivotal driver of the Europe Protein Sequencing Market, significantly
influencing advancements in proteomics research and application. In 2023,
the European Union allocated substantial resources to health and life sciences
under its Horizon Europe program, emphasizing the integration of protein
sequencing technologies to address complex health challenges. Specifically, the
Horizon Europe Work Programme 2023-2025 highlighted missions targeting cancer,
including initiatives to enhance early diagnosis and treatment through advanced
proteomic analysis. These missions aim to foster systemic solutions,
leading to societal transformations and social impact.
In the United Kingdom, government initiatives have
further bolstered the proteomics landscape. The UK Biobank, supported by both
government and private sector funding, has become a cornerstone for proteomics
research. In 2023, it released plasma proteomic data from approximately
53,000 participants, generated using Olink's Proximity Extension Assay
technology. This initiative, backed by a consortium of pharmaceutical
companies, underscores the UK's commitment to advancing proteomic research and
its applications in understanding human health.
These concerted efforts reflect a strategic alignment
between funding bodies and research institutions, driving innovation and
adoption of protein sequencing technologies across Europe. As academic and
government funding continues to rise, the demand for advanced proteomics tools
is expected to grow, further propelling the expansion of the protein sequencing
market in the region.
Growing
Proteomics Research in Drug Discovery and Development
The escalating emphasis on proteomics research within
drug discovery and development is a significant driver of the Europe Protein
Sequencing Market, particularly in the United Kingdom. In 2023, the UK
Biobank released whole genome sequencing data for all 500,000 participants,
marking the largest such dataset ever made available for medical research.
This initiative was supported by UK Research and Innovation (UKRI), Wellcome,
and industry partners like Amgen, AstraZeneca, GSK, and Johnson & Johnson,
with sequencing conducted by deCODE Genetics and the Wellcome Sanger Institute.
In October 2023, the UK Biobank, in
collaboration with 14 pharmaceutical companies, launched a proteomics project
to utilize artificial intelligence (AI) in understanding and treating diseases. This project
aims to leverage the UK's extensive genetic database to train AI models,
identifying precise disease subtypes for tailored treatments. The initiative is
expected to enhance AI models, supported by advancements like Google's
AlphaFold for protein structure prediction, thereby revolutionizing disease
understanding and intervention.
These substantial investments and initiatives
underscore the UK's commitment to advancing proteomics research, thereby
driving the demand for protein sequencing technologies in the region. As the
focus shifts towards personalized medicine and targeted therapies, the need for
comprehensive protein analysis becomes increasingly critical, further
propelling market growth.
Download Free Sample Report
Key Market Challenges
High
Cost of Equipment and Consumables
One of the primary challenges faced by the Europe
Protein Sequencing Market is the high cost of equipment and consumables. The
advanced technologies used in protein sequencing, such as mass spectrometry and
next-generation sequencing platforms, involve substantial initial investments.
The sophisticated instruments required for high-throughput sequencing are not
only expensive to purchase but also incur high maintenance and operational
costs. This includes expenses for calibration, upgrades, and the skilled technical
support needed to ensure optimal performance, which can be a significant
financial burden for many research institutions and laboratories, especially in
smaller or emerging markets.
The consumables required for protein sequencing, such
as reagents, chips, and other consumable items, are also costly. These ongoing
expenses contribute to the overall cost of performing sequencing experiments,
limiting the accessibility of protein sequencing technologies for smaller
companies and research institutions. The high costs may prevent widespread
adoption and use of these technologies, particularly in academic research
settings where funding can be limited.
In addition, as the demand for more detailed and
accurate protein sequencing increases, the cost of consumables could rise
further due to the complexity and specificity required for different types of
analysis. This poses a barrier for many players, particularly those in the
early stages of adoption or those in cost-sensitive sectors. For the market to
experience sustained growth, companies will need to focus on making protein
sequencing more affordable by reducing the costs associated with equipment, consumables,
and maintenance, allowing broader access to these advanced technologies.
Data
Complexity and Interpretation Challenges
The Europe Protein Sequencing Market faces significant
challenges related to data complexity and interpretation. Protein sequencing
generates vast amounts of complex data, which can be difficult to process and
interpret accurately. Unlike genomic sequencing, which focuses on DNA, protein
sequences are more intricate due to the vast diversity of proteins and their
post-translational modifications. These modifications, which include
phosphorylation, glycosylation, and ubiquitination, can substantially affect protein
function and behavior. As a result, interpreting these variations in a
meaningful way requires sophisticated algorithms, specialized knowledge, and
advanced computational tools.
The complexity of the data makes it challenging for
researchers and clinicians to derive actionable insights from the protein
sequences. The large volume of data, combined with the need for high-resolution
analysis, puts pressure on computational resources and bioinformaticians who
must ensure that the data is processed correctly. In some cases, errors in data
interpretation can lead to inaccurate conclusions, which can impact research
findings, clinical decisions, and the development of therapeutic solutions.
Another challenge lies in the integration of protein sequencing
data with other omics data, such as genomics and transcriptomics. Combining
these different data types to provide a holistic view of biological processes
adds an additional layer of complexity. The lack of standardized methods for
data integration and interpretation also hinders the widespread adoption of
protein sequencing technologies. These factors pose barriers to achieving the
full potential of protein sequencing, limiting its impact on drug discovery,
personalized medicine, and disease understanding in the Europe Protein
Sequencing Market.
Key Market Trends
Integration
of AI and Machine Learning in Protein Analysis
The integration of AI and Machine
Learning (ML) in protein analysis is a significant trend driving the Europe
Protein Sequencing Market. AI and ML technologies are revolutionizing how
protein sequences are analyzed and interpreted, offering unprecedented
capabilities in handling large, complex datasets generated by protein
sequencing technologies. These advanced algorithms enhance the efficiency and
accuracy of protein identification, structural analysis, and functional
prediction, which are crucial in fields such as drug discovery, disease
research, and biomarker identification.
AI and ML facilitate the processing of
massive amounts of protein data at much faster rates than traditional methods,
enabling researchers to extract meaningful insights and patterns that may not
be apparent through manual analysis. For instance, AI-driven tools can predict
protein structures and interactions, helping to identify potential therapeutic
targets more quickly. Machine learning models, trained on extensive protein
databases, can also identify correlations between protein variations and disease
states, which is essential for developing personalized medicine and targeted
therapies.
In the context of drug discovery, the
use of AI and ML in protein analysis accelerates the identification of
candidate molecules and streamlines the early stages of drug development. AI
and ML algorithms assist in identifying promising drug targets by analyzing
protein biomarkers associated with specific diseases. As these technologies
continue to evolve, they offer even greater precision and the potential to
uncover new biological insights that can transform therapeutic approaches and
improve patient outcomes. This trend is significantly enhancing the efficiency
of protein sequencing, making it a valuable tool for researchers across Europe.
Shift
Toward De Novo Protein Sequencing
A significant trend in the Europe Protein Sequencing
Market is the shift toward De Novo Protein Sequencing, a method that is gaining
traction due to its ability to identify novel proteins without the need for
prior sequence information. This approach is particularly valuable in studying
proteins from organisms or tissues that lack complete genomic sequences or when
investigating post-translational modifications that are difficult to detect
using traditional sequencing techniques. De novo protein sequencing allows
researchers to directly determine the amino acid sequence of proteins, enabling
deeper insights into protein structure and function.
The increasing complexity of proteomics studies and
the need for more accurate and comprehensive data on protein function have
fueled this shift. Traditional sequencing methods often rely on known reference
databases to map protein sequences, which can limit the discovery of novel or
rare proteins. In contrast, de novo sequencing removes this dependency,
allowing for a broader exploration of proteomic diversity. This trend is
particularly important in drug discovery, biomarker identification, and disease
research, where identifying previously undetected proteins can lead to the
development of more targeted and personalized therapies.
As the demand for more precise and in-depth protein
analysis grows, de novo sequencing methods are being integrated into research
pipelines across various industries, from pharmaceutical companies to academic
institutions. The advancement of sequencing technologies, such as mass
spectrometry and high-resolution protein sequencing platforms, has made de novo
sequencing more accessible, reliable, and cost-effective. As a result, the move
toward de novo protein sequencing is expected to continue driving growth in the
European protein sequencing market.
Segmental Insights
Product
& Service Insights
Based
on the Product & Service, Protein Sequencing Products emerged as the
dominant segment in the Europe Protein Sequencing Market in
2024. This is due to their critical role in advancing proteomics
research and drug discovery. These products include advanced instruments,
reagents, and consumables designed for high-throughput and high-resolution
protein sequencing. The increasing need for precision medicine and personalized
therapies has significantly driven demand for these products, as they enable
the identification and analysis of biomarkers crucial for disease diagnosis and
treatment. Europe’s growing investment in life sciences research, especially in
biotech and pharmaceutical sectors, has further propelled the adoption of
protein sequencing technologies. Researchers rely on these products for
studying protein functions, interactions, and modifications, which are
essential for understanding complex diseases like cancer, neurological
disorders, and cardiovascular diseases.
End
User Insights
Based on the End User, Pharmaceutical
& Biotechnology Companies emerged as the dominant segment in the Europe Protein Sequencing
Market in 2024. This is due to their crucial role in drug
discovery, biomarker identification, and therapeutic development. These
companies heavily invest in protein sequencing technologies to gain insights
into protein structure, function, and interactions, which are vital for understanding
disease mechanisms and identifying novel drug targets. Protein sequencing plays
a pivotal role in the development of biologics, including monoclonal antibodies
and other protein-based therapeutics, which have seen increased demand in both
research and clinical settings. The rapid growth of personalized medicine and
the increasing shift toward precision healthcare have driven pharmaceutical and
biotechnology companies to adopt advanced proteomics technologies. The ability
to accurately sequence proteins enables the identification of specific
biomarkers linked to diseases such as cancer, neurological disorders, and
autoimmune diseases, thus aiding in early diagnosis and targeted treatments.
Download Free Sample Report
Country Insights
Germany emerged as the
dominant country in the Europe Protein Sequencing Market in 2024. This is due to its strong presence in the
life sciences and biotechnology sectors. Germany is home to numerous leading
pharmaceutical, biotechnology, and research institutions that are at the
forefront of protein research, drug discovery, and medical diagnostics. The
country’s advanced infrastructure, robust research ecosystem, and significant
investments in life sciences have created a favorable environment for the adoption
of protein sequencing technologies. Germany’s commitment to innovation,
supported by government initiatives and research grants, has fostered the
development of cutting-edge protein sequencing platforms. The country also
benefits from a highly skilled workforce and strong collaborations between
academic institutions and industry players, enhancing the pace of discovery and
commercialization of new proteomics solutions. Additionally, Germany’s strong
healthcare system and focus on precision medicine further contribute to the
demand for protein sequencing technologies.
Recent Developments
- In February 2025, Africa’s EVA Pharma, France’s DNA
Script, and Belgium’s Quantoom Biosciences signed a Memorandum of Understanding
during the 2nd Vaccine and Other Health Products Manufacturing Forum in Cairo.
The partnership aims to create the first digital-to-biologics mRNA production
platform, focused on nucleic acid-based vaccines and therapeutics for human and
animal health. The platform, based in Egypt, will integrate DNA Script’s
enzymatic DNA synthesis, Quantoom’s mRNA synthesis and formulation technologies,
and EVA Pharma’s vaccine development and GMP sterile manufacturing expertise.
- In December 2024, Quantum-Si
Incorporated (Nasdaq: QSI), known as The Protein Sequencing Company, announced
the expansion of its international distribution network to 15 partners. This
includes broader coverage across Western and Eastern Europe, Asia, and new
market entries in the Middle East, Africa, South America, and the South
Pacific.
- In May 2024, Element Biosciences, a leader in
innovative scientific technologies, highlighted the growing adoption of its
AVITI System sequencer at the European Human Genetics Conference (ESHG) 2024 in
Berlin, Germany, presented the AVITI24 platform, which integrated advanced
sequencing and multiomic cell analysis. This cutting-edge system allowed for
simultaneous analysis of DNA, RNA, proteins, phosphorylated proteins, and
morphology in up to one million cells per flow cell, advancing biological
research and offering powerful tools for the scientific community.
- In October 2023, Thermo Fisher Scientific Inc. announced
its proposal to acquire Olink Holding AB for USD 26.00 per share in cash. Thermo
Fisher will initiate a tender offer to acquire all outstanding common shares
and American Depositary Shares of Olink. Olink, based in Sweden, provides
advanced proteomics solutions through its proprietary Proximity Extension Assay
(PEA) technology, enabling efficient protein analysis for disease
understanding. The company has a strong presence in the Americas, Europe, and
Asia Pacific, with over 1,400 scientific publications supporting the widespread
adoption of its technology.
Key Market Players
- Thermo
Fisher Scientific
- SCIEX
Europe
- Biognosys
AG
- Evotec
SE
- Sartorius
AG
- Proteome
Sciences plc
- Biotage
AB
- Eurofins
Genomics Europe
- Toplab
GmbH
- Mass
Analytica S.L.
|
By Product & Service
|
By Application
|
By End User
|
By Country
|
- Protein Sequencing Products
- Protein Sequencing Services
|
- Bio-therapeutics
- Genetic Engineering
- Others
|
- Academic Institutes & Research Centers
- Pharmaceutical & Biotechnology Companies
- Others
|
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Poland
- Bulgaria
- Finland
- Portugal
|
Report Scope:
In this report, the Europe
Protein Sequencing Market has been segmented into the following categories, in
addition to the industry trends which have also been detailed below:
- Europe
Protein Sequencing Market, By Product & Service:
o
Protein
Sequencing Products
·
Reagents
& Consumables
·
Instruments
·
Software
o
Protein
Sequencing Services
- Europe
Protein Sequencing Market, By Application:
o
Bio-therapeutics
o
Genetic
Engineering
o
Others
- Europe
Protein Sequencing Market, By End User:
o
Academic
Institutes & Research Centers
o
Pharmaceutical
& Biotechnology Companies
o
Others
- Europe
Protein Sequencing Market, By Country:
o
Germany
o
France
o
United
Kingdom
o
Italy
o
Spain
o
Russia
o
Poland
o
Bulgaria
o
Finland
o
Portugal
Competitive Landscape
Company
Profiles: Detailed
analysis of the major companies present in the Europe Protein Sequencing Market.
Available Customizations:
Europe Protein Sequencing Market report with the given market data,
TechSci Research offers customizations according to a company's specific needs.
The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to
five).
Europe Protein Sequencing Market is an upcoming report to be released
soon. If you wish an early delivery of this report or want to confirm the date
of release, please contact us at sales@techsciresearch.com